Suppr超能文献

氟喹诺酮耐药突变对淋球菌适应性和体内补偿性突变选择的影响。

Impact of fluoroquinolone resistance mutations on gonococcal fitness and in vivo selection for compensatory mutations.

机构信息

Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.

出版信息

J Infect Dis. 2012 Jun 15;205(12):1821-9. doi: 10.1093/infdis/jis277. Epub 2012 Apr 5.

Abstract

BACKGROUND

Quinolone-resistant Neisseria gonorrhoeae (QRNG) arise from mutations in gyrA (intermediate resistance) or gyrA and parC (resistance). Here we tested the consequence of commonly isolated gyrA(91/95) and parC86 mutations on gonococcal fitness.

METHODS

Mutant gyrA(91/95) and parC86 alleles were introduced into wild-type gonococci or an isogenic mutant that is resistant to macrolides due to an mtrR(-79) mutation. Wild-type and mutant bacteria were compared for growth in vitro and in competitive murine infection.

RESULTS

In vitro growth was reduced with increasing numbers of mutations. Interestingly, the gyrA(91/95) mutation conferred an in vivo fitness benefit to wild-type and mtrR(-79) mutant gonococci. The gyrA(91/95), parC86 mutant, in contrast, showed a slight fitness defect in vivo, and the gyrA(91/95), parC86, mtrR(-79) mutant was markedly less fit relative to the parent strains. A ciprofloxacin-resistant (Cip(R)) mutant was selected during infection with the gyrA(91/95), parC86, mtrR(-79) mutant in which the mtrR(-79) mutation was repaired and the gyrA(91) mutation was altered. This in vivo-selected mutant grew as well as the wild-type strain in vitro.

CONCLUSIONS

gyrA(91/95) mutations may contribute to the spread of QRNG. Further acquisition of a parC86 mutation abrogates this fitness advantage; however, compensatory mutations can occur that restore in vivo fitness and maintain Cip(R).

摘要

背景

耐喹诺酮淋病奈瑟菌 (QRNG) 是由 gyrA(中度耐药)或 gyrA 和 parC(耐药)突变引起的。在这里,我们测试了常见分离的 gyrA(91/95) 和 parC86 突变对淋球菌适应性的影响。

方法

将突变 gyrA(91/95) 和 parC86 等位基因引入野生型淋球菌或因 mtrR(-79)突变而对大环内酯类药物耐药的同源突变体中。比较野生型和突变型细菌在体外和竞争感染中的生长情况。

结果

随着突变数量的增加,体外生长能力降低。有趣的是,gyrA(91/95)突变赋予野生型和 mtrR(-79)突变淋球菌体内适应性优势。相比之下,gyrA(91/95)、parC86 突变体在体内适应性略差,而 gyrA(91/95)、parC86、mtrR(-79)突变体相对于亲本菌株适应性明显降低。在感染 gyrA(91/95)、parC86、mtrR(-79)突变体时,选择出一种对环丙沙星耐药(Cip(R))的突变体,其中 mtrR(-79)突变被修复,gyrA(91)突变发生改变。这种体内选择的突变体在体外与野生型菌株生长一样良好。

结论

gyrA(91/95)突变可能有助于 QRNG 的传播。进一步获得 parC86 突变会消除这种适应性优势;然而,可能会发生补偿性突变,恢复体内适应性并维持 Cip(R)。

相似文献

引用本文的文献

本文引用的文献

5

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验